Maia Biotechnology Inc (MAIA) Share Price

I believe its a scam

if the insiders werent buying common stock i would be so sure this is another Theranos. Complete flim flam

New offering just raised 2.44 million …..and the share price acted positively

Hard to tell.

The company had almost $12m in cash at the end of the last quarter, and had just under $4m in expenses last quarter.

The company also has an active ATM, that they stated would likely be active through end of this quarter.

Given all that, probably not a new offering but any pop will get diluted via their ATM.

Murocman

MAIA under $4

Raise coming?

MAIA...HERE COMES 6 BUCKS

MAIA...HERE WE GO

MAIA MONSTER BIO

MAIA ANOTHER BIO BEAST SETTING UP ON THE WEEKLY!!

CHICAGO--(BUSINESS WIRE)--May 16, 2024--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract about its Phase 2 THIO-101 clinical trial named “A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results” was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, to take place May 31-June 4, 2024, in Chicago, Illinois. The poster is scheduled for presentation on June 3, 2024, from 1:30pm to 4:30pm CST.

“We are proud to accept ASCO’s invitation to present at its 2024 Annual Meeting, the most significant gathering of oncology professionals worldwide,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “We look forward to revealing the newest efficacy results from THIO-101 and discussing our pioneering telomere targeting science underlying THIO, the first and only cancer treatment of its kind in clinical development.”

MAIA’s abstract will be available online at the ASCO Annual Meeting 2024 website during the week prior to the conference start date, and the poster will be published on maiabiotech.com on the day of the presentation, June 3, 2024.

MAIA under $

Pricing now at a 52 week high, which is going against the bearish trend in the medtech sector which peaked in February
This is a good thing

MAIA no longer under 3$

I wouldn’t be surprised with all the form 4s. I think there’s still a lot of legwork to be done via trials to unlock value here, but a partner would be nice. All those form 4s though seem to be essentially raising funds, so I’m not sure a partner is quite there yet. We’ll see. I just started a position here in late Feb, wish I had built up more before this run.

Have ASCO on watch :)
I believe partner is coming q2.

Lot of potential, looking forward to continued data readouts.

I believe MAIA can go to 4-20bln mcap. Look at the recent presentation @bs3500.

More boom than we’ve had?

will go boom soon

MAIA......................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

3/22 news On March 11, 2024, MAIA entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of 2,043,587 shares of the Company’s common stock, and warrants to purchase up to 2,043,587 shares of the Company’s common stock, at a price per share of $1.17. The combined gross proceeds from the private placement, closed on March 14, 2024, were approximately $2.9 million, prior to deducting offering expenses payable by the Company.

Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer, commented, “The participation in our private placement from five of our independent directors points to their confidence in the science and clinical pathways for our immuno-oncology therapies targeting difficult-to-treat cancers.”

Stan V. Smith, Ph.D., added, “I have participated in every round of financing and I am a big believer in MAIA’s telomere-targeting approach to cancer and its potential to disrupt the field of research and development for cancer therapies, for the benefit of all humankind.”

Dr. Smith is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

MAIA no longer under $2

MAIA 10Q due 3/22

$MAIA Thank you. I bought 1.52 blockbuster news...
https://ih.advfn.com/stock-market/AMEX/maia-biotechnology-MAIA/stock-news/93435486/maia-biotechnology-announces-strong-efficacy-of-th

https://ih.advfn.com/stock-market/AMEX/maia-biotechnology-MAIA/stock-news/93435486/maia-biotechnology-announces-strong-efficacy-of-th

MAIA...............................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

https://www.stocktitan.net/news/MAIA/maia-biotechnology-completes-enrollment-in-thio-101-phase-2-clinical-wlx7kik4ysk4.html

MAIA........................................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA...............................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA..............................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA..................................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA...........................................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA....................................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA.................................................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA new 52 week low

MAIA new 52 week low

2.00s now. nice add

Adding

https://www.nasdaq.com/market-activity/spos

MAIA MAIA Biotechnology, Inc. 6/08/2023 $5,750,000

https://stockcharts.com/h-sc/ui?s=maia&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/maia/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100

https://www.barchart.com/stocks/quotes/maia/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/maia/opinion

https://finance.yahoo.com/quote/maia/

What offering?

I just found out about this company.

Thanks

Don’t be so sure. The offering just closed. There might not be much left to gain from further shorting. The stock could stabilize quickly.

Not today LOL.

No shit! You know, a post like that, after 265 days of silence, might be considered bullish. Time to resurrect the Maya. LOL.

More sellers than buyers.....

why is the ask $33?

MAIA Biotechnology Announces Pricing of Initial Public Offering
7:52 pm ET July 27, 2022 (BusinessWire) Print
MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its initial public offering of 2,000,000 shares of the Company's common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $10,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less discounts and commissions, to cover over-allotments.

The shares of common stock are expected to begin trading on the NYSE American under the ticker symbol "MAIA" on July 28, 2022. The offering is expected to close on August 1, 2022, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the initial public offering to fund the first part of the Phase 2 trials of the Company's product candidate THIO, pre-clinical development of second-generation of telomere targeting compounds and other research and development activities, as well as for working capital and other general corporate purposes.

ThinkEquity is acting as sole book-running manager for the offering.

The registration statement on Form S-1 (file No. 333-264225) relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and became effective on July 27, 2022. A final prospectus related to the proposed offering will be filed and made available on the SEC's website at https://www.sec.gov/. The offering is being made only by means of a prospectus. Electronic copies of the final prospectus may be obtained, when available, from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673 and by email at prospectus@think-equity.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MAIA Biotechnology, Inc.

MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

This press release includes forward-looking statements including, but not limited to, statements related to the closing of the offering and the expected use of proceeds, development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220727006179/en/

SOURCE: MAIA Biotechnology, Inc.



Investor Inquiries
ICR Westwicke
Stephanie Carrington
Stephanie.carrington@westwicke.com
646-277-1282

MAIA Biotechnology, Inc. is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. The Company’s pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers. The Company's THIO (6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is a telomere-by-telomerase targeting agent for the treatment of multiple cancer types. THIO is followed by Libtayo for the treatment of advanced non-small-cell lung cancer. The Company's 2nd-generation program is engaged in discovering new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. The 2nd-generation pipeline of potential telomere-targeting agents includes five compounds that have undergone in vitro inhibitory testing in five cancer models. The Company's subsidiary is MAIA Biotechnology Australia Pty Ltd.